Graphium Biosciences

Biotechnology ResearchCalifornia, United States2-10 Employees

Graphium Biosciences, located in Los Angeles, California, operates as a wholly owned subsidiary of Malachite Innovations and concentrates on developing pharmaceutical-grade cannabinoid therapies for inflammatory bowel disease. Its approach centers on a glycosylation process that bonds glucose to cannabinoids, creating glycosylated compounds intended to rebalance the endocannabinoid system and reduce GI inflammation without producing psychoactive effects. The firm's leading compound, VBX-100, is a glycosylated THC variant that has received FDA Orphan Drug Designation for pediatric ulcerative colitis. The company has developed a portfolio of over 250 glycosylated cannabinoids and endocannabinoids, with patent coverage backing these candidates. This positioning places Graphium within the wider field of targeted IBD therapeutics. Based in a small team setting, Graphium outlines a plan to advance VBX-100 through the remaining animal studies and early-stage clinical testing over a three-year period.

Sign up for free to view info

Email Format Employee directory